Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931352 | 0.99 | MAOA (0.54) | MAOAMAOBALDH1A1KAT6AALOX15 | |
| SCHEMBL930417 | 0.99 | MAOA (0.54) | MAOAMAOBALDH1A1KAT6AALOX15 | |
| SCHEMBL930973 | 0.97 | MAOA (0.49) | MAOAMAOBALDH1A1KAT6AALOX15 | |
| SCHEMBL6487958 | 0.87 | KMT2A (0.51) | ALDH1A1RAB9AMEN1KMT2AATM | |
| SCHEMBL12093099 | 0.85 | EPHX2 (0.49) | ALOX15EPHX2MEN1KMT2AATM | |
| SCHEMBL20919714 | 0.84 | EPHX2 (0.58) | ALDH1A1KAT6ARAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL7699337 | 0.84 | SLC5A7 (0.55) | RAB9AMEN1KMT2AOPRK1 | |
| SCHEMBL26933282 | 0.84 | F10 (0.49) | MAOAMEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL26933289 | 0.84 | F10 (0.49) | MAOAMEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL6487966 | 0.83 | PDE4D (0.45) | MEN1KMT2AATMCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183660-A1 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | SENOMYX, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2448944-A2 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | Senomyx, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002871-A2 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | SENOMYX, INC (US) | 2011-01-06 | — | — | WO | disclosed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| CN-1178932-C | Amide derivatives | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1350530-A | Amide derivatives | ASTRAZENECA AB (SE) | 2002-05-22 | — | — | CN | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAOA 1506/4885MAOB 1262/4885ALDH1A1 269/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAOA 1506/4885MAOB 1262/4885ALDH1A1 269/4885 |
| US-20120183660-A1 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | TAS2R41, TAS2R42, TAS2R40 | MAOA 3025/4885MAOB 3519/4885ALDH1A1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.